October 16, 2018
Rose
The rule, which is part of President Donald Trump's blueprint to rein in high drug costs, sparked immediate push back from pharmaceutical companies. Beyond the industry, experts are skeptical that the regulation would do anything to bring down prices and may confuse patients because consumers often don't pay the list price for medications.
from Kaiser Health News https://ift.tt/2Ck1AHW
October 16, 2018
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Tufts University Latest Organization To Distance Itself From Sackler Family Following Opioid Crisis Fallout- New Concepts About Mental Health Of Vets: Bad War Experiences Might Not Be What’s Leading To So Many Suicides
- Supreme Court’s Question Of The Day: Does The Constitution Give Homeless The Right To Sleep On Sidewalks?
- Nearly One In Three High School Students Admit To Using At Least One Type Of Tobacco Product Recently
- Medicare Advisory Commission Deems Payments To Ambulatory Surgical Centers As Already High Enough
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment